TW200619206A - Chemokine-binding heterocyclic compound salts, and methods of use thereof - Google Patents

Chemokine-binding heterocyclic compound salts, and methods of use thereof

Info

Publication number
TW200619206A
TW200619206A TW094132888A TW94132888A TW200619206A TW 200619206 A TW200619206 A TW 200619206A TW 094132888 A TW094132888 A TW 094132888A TW 94132888 A TW94132888 A TW 94132888A TW 200619206 A TW200619206 A TW 200619206A
Authority
TW
Taiwan
Prior art keywords
methods
chemokine
heterocyclic compound
compound salts
binding heterocyclic
Prior art date
Application number
TW094132888A
Other languages
English (en)
Inventor
Jason Crawford
Yong-Bao Zhu
Gang Chen
Ian R Baird
Renato T Skerlj
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of TW200619206A publication Critical patent/TW200619206A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW094132888A 2004-09-29 2005-09-22 Chemokine-binding heterocyclic compound salts, and methods of use thereof TW200619206A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61479004P 2004-09-29 2004-09-29

Publications (1)

Publication Number Publication Date
TW200619206A true TW200619206A (en) 2006-06-16

Family

ID=36142992

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094132888A TW200619206A (en) 2004-09-29 2005-09-22 Chemokine-binding heterocyclic compound salts, and methods of use thereof

Country Status (10)

Country Link
US (1) US7723525B2 (zh)
EP (1) EP1799215B1 (zh)
JP (1) JP5209314B2 (zh)
CN (1) CN101111249B (zh)
BR (1) BRPI0515918B8 (zh)
CA (1) CA2582911C (zh)
ES (1) ES2581559T3 (zh)
MX (1) MX2007003861A (zh)
TW (1) TW200619206A (zh)
WO (1) WO2006039250A2 (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
EP2055705A4 (en) 2006-07-31 2014-08-20 Ono Pharmaceutical Co COMPOUND WITH A CYCLIC GROUP BOUND BY A SPIRO BINDING THEREOF AND APPLY THEREOF
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
WO2017106328A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
PT3393468T (pt) 2015-12-22 2023-01-19 X4 Pharmaceuticals Inc Métodos para tratar imunodeficiências
EP3440112A4 (en) 2016-04-08 2019-10-09 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US11433048B2 (en) 2016-06-16 2022-09-06 Centre National De La Recherche Scientifique CXCR4 receptor-binding compounds useful for increasing interferon level
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN116554168A (zh) 2016-06-21 2023-08-08 X4 制药有限公司 Cxcr4抑制剂及其用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US20220017487A1 (en) * 2020-07-16 2022-01-20 X4 Pharmaceuticals, Inc. Deuterated compounds and uses thereof
EP4085910A1 (en) * 2021-05-05 2022-11-09 4Living Biotech Use of a compound such as plerixafor for treating a viral pulmonary disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
KR20010015639A (ko) * 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
AU2001252350A1 (en) * 2000-04-13 2001-10-30 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
US6767915B2 (en) * 2000-08-23 2004-07-27 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
ATE425157T1 (de) * 2000-09-15 2009-03-15 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
CN1237061C (zh) * 2000-09-15 2006-01-18 阿诺麦德股份有限公司 结合趋化因子受体的杂环化合物
DE10161963A1 (de) * 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
JP4556020B2 (ja) 2001-12-21 2010-10-06 ジェンザイム・コーポレーション 高い有効性を有するケモカインレセプタ結合複素環式化合物
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DOP2003000556A (es) * 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
RU2312861C2 (ru) * 2002-03-05 2007-12-20 Мерк Фросст Кэнада Лтд. Ингибиторы катепсин-цистеинпротеазы
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
BRPI0508703B8 (pt) * 2004-03-15 2021-05-25 Anormed Inc processo para a síntese de um antagonista de cxcr4

Also Published As

Publication number Publication date
CA2582911C (en) 2013-12-10
WO2006039250A2 (en) 2006-04-13
US7723525B2 (en) 2010-05-25
EP1799215A2 (en) 2007-06-27
BRPI0515918B1 (pt) 2021-04-13
BRPI0515918B8 (pt) 2021-05-25
BRPI0515918A (pt) 2008-08-12
US20060069122A1 (en) 2006-03-30
ES2581559T3 (es) 2016-09-06
EP1799215B1 (en) 2016-06-01
JP2008514708A (ja) 2008-05-08
EP1799215A4 (en) 2010-08-18
CN101111249B (zh) 2011-01-19
CN101111249A (zh) 2008-01-23
JP5209314B2 (ja) 2013-06-12
WO2006039250A3 (en) 2006-10-19
BRPI0515918A8 (pt) 2020-02-11
CA2582911A1 (en) 2006-04-13
MX2007003861A (es) 2008-02-19

Similar Documents

Publication Publication Date Title
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
TN2010000148A1 (en) Amide compound
TW200624426A (en) BACE inhibitors
TW200637837A (en) Fungicides
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
IL192102A0 (en) 1,3-oxazolidin-2-one derivatives useful as cetp inhibitors
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
IL192033A0 (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
MX2010004493A (es) Compuestos de tropano.
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
EA201000395A1 (ru) Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
TW200736195A (en) Methods for preparing sulfonamide substituted alcohols and intermediates thereof
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
TW200732281A (en) Heterocyclic CETP inhibitors
TN2010000064A1 (en) Novel herbicides
TNSN08191A1 (en) Kinase inhibitors
MX2010001364A (es) Derivados de ciclopentandiona puenteados triciclicos como herbicidas.
HK1111995A1 (en) Substituted imidazole compounds as ksp inhibitors
TW200619205A (en) A method for preparing irbesartan and intermediates thereof
UA106880C2 (uk) Нові гербіциди
WO2007062314A3 (en) Heterocyclic cetp inhibitors
EA201200891A1 (ru) Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина
TW200730521A (en) Triazine compounds having amino-and carboxyl-containing substituents